Difficult year for Biotechnology so far, down -17% YTD. Fundamentally the sector is gaining strength. Meaningful policy clarity to be achieved in 6-weeks based on election outcome. Biotechnology is ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Microrobots have long promised precision drug delivery inside the human body, but making them practical has remained difficult. Many designs are complex, expensive to manufacture, or hard to control ...